Nootropics are sold as a flat list — twenty things that all vaguely “help focus.” They aren’t flat. They act at four distinct layers of the brain, and the layer decides everything: how fast you feel it, how deep it goes, how strong the evidence is, and whether two things stack or cancel. Here is the map.
Ask what Alpha-GPC, DHA, methylene blue, and Dihexa “do for the brain” and you’ll get four answers that all sound the same: improves cognition. That flatness is exactly why this category is the most hype-saturated corner of health. The truth is that these four don’t compete at all — they operate at completely different layers of the same organ. One supplies a neurotransmitter’s raw material. One is the physical material neurons are built from. One moves electrons in mitochondria. One forces a growth pathway. Sort them by layer and the fog lifts: you can see instantly which things are redundant, which genuinely complement each other, which are foundational, and which are marketing wearing a mechanism costume.
Read it top to bottom: signal (what fires), structure (what the brain is made of), energy (what powers all of it), and growth (rewiring). Color marks evidence, not enthusiasm.
This is the layer everything markets itself on, because it’s the layer you feel. It splits into two systems: the cholinergic (attention/memory) and the catecholamine/calm axis (drive vs. ease).
Acetylcholine is the neurotransmitter of attention, learning, memory encoding, and focus — it sharpens signal-to-noise in the cortex. It’s the “engage with the task” signal, and essentially every focus product is aimed here. The interesting part is that the popular agents hit it at different points.
A choline donor that crosses the blood-brain barrier well. It doesn’t push the system — it stocks the shelves, supplying the raw material neurons build acetylcholine from. Reasonable human evidence for cognition, strongest where cholinergic tone is low. Think substrate, not stimulant.
Doesn’t supply anything — it pulls the trigger directly on nicotinic acetylcholine receptors. The acute effects on attention, working memory, and reaction time are well documented and real. So is the rest of it: it’s genuinely addictive, it upregulates its own receptors (tolerance → dependence → withdrawal that itself impairs cognition), and it constricts vessels and raises heart rate and blood pressure. The cognitive benefit is real; the dependence liability is the dominant fact.
The rationale is genuinely coherent: nicotine stimulates the receptor while Alpha-GPC keeps the choline tank full, so your own acetylcholine synthesis can keep up with the stimulation — two different points on one system. But two honest problems. First, there is no good human trial of that specific combination — it’s a community stack built on plausible reasoning, not evidence. Second, and more importantly, an elegant mechanism doesn’t neutralize an addiction profile. Whether this is a good idea is decided by nicotine’s dependence liability, not by how nicely the diagram fits together. That’s the whole lesson of mechanistic thinking done honestly: the wiring tells you how it works, not whether you should.
The amino-acid precursor to dopamine and norepinephrine — drive, motivation, alertness. The nuance that matters: it mainly helps when catecholamines are being depleted — acute stress, sleep deprivation, cold, heavy cognitive load. Rested and normal, you aren’t substrate-limited and it does relatively little. It’s a buffer under stress, not a daily stimulant.
Promotes alpha brain waves — relaxed alertness. Takes the edge off stimulants without sedating. Modest but real and very well tolerated. The opposite pole from tyrosine, which is why they can balance or cancel depending on what you actually want.
Magnesium blocks the NMDA receptor’s calcium channel, damping excess excitatory glutamate signaling — the mechanistic basis of its calming/sleep effect. The glycinate form isn’t incidental: glycine is itself an inhibitory neurotransmitter that supports sleep, so the carrier contributes. (For brain penetration specifically, magnesium L-threonate is the form with dedicated research — though the evidence is thinner than the marketing.)
The quietest layer and the most underrated. You never feel it working, which is exactly why it gets skipped — and why it has the highest floor-raising value over a lifetime.
This isn’t a signal — it’s the material your brain is built from. DHA is among the most abundant fatty acids in the brain, concentrated in synaptic membranes, where it governs membrane fluidity — which determines how receptors sit and signal. It’s also anti-inflammatory (via resolvins) and supports cerebral blood flow. Slow, unglamorous, cumulative: it doesn’t sharpen your afternoon, it shapes the organ.
Really a hormone, with receptors throughout the brain — involved in neurotrophic factor expression, neuroinflammation regulation, and calcium handling. Deficiency is associated with cognitive decline and low mood. The honest framing: correcting a deficiency matters far more than topping up when you’re already replete — this is a fix-the-gap nutrient, not a dose-response booster.
Here as D’s partner and the traffic cop for calcium — directing it into bone and away from arteries. That’s cerebrovascular protection rather than direct brain signaling. But blood flow is brain function, so it earns its place at the structural layer by protecting the plumbing.
Here is the fact that makes this layer non-optional: your brain is about 2% of your body weight and burns about 20% of your energy. It is the most energy-hungry tissue you own — which makes it the tissue most exposed to any mitochondrial shortfall, and the reason mitochondrial agents show up in cognition at all. Every signal in Layer 1 is drawn on this account.
An alternative electron carrier — it can shuttle electrons within the electron transport chain, bypassing sluggish complexes. That’s directly addressing energy throughput in the most energy-demanding tissue, which is why it’s the mitochondrial agent people most often report as cognitively noticeable. Critical caveats: a strongly U-shaped dose-response (low dose helps, higher does the opposite), serotonin-syndrome risk with SSRIs and other serotonergic drugs, and it is contraindicated in G6PD deficiency. This one is not a “more is better” compound in any sense.
The electron carrier the whole chain runs on, and the substrate sirtuins require. Brain relevance runs through energy production and mitochondrial quality control. Honest caveat: how well oral precursors raise brain NAD⁺ specifically is debated — most of the solid human data is peripheral, not central.
Works via AMPK, driving mitochondrial biogenesis and metabolic flexibility. But be honest about the tier: the brain-specific evidence is thin. The data is largely metabolic and systemic; cognitive benefit is a reasonable extrapolation from better mitochondrial function, not a demonstrated effect.
CoQ10 is another electron carrier (brain penetration is limited). PQQ is a mitochondrial-biogenesis signal. ALCAR is the interesting one — it carries fatty acids into mitochondria and donates an acetyl group for acetylcholine synthesis, making it the single agent that genuinely sits in both the energy and cholinergic layers.
Brain-specifically, there is essentially nothing. NNMT is expressed in brain, so an argument exists in principle, but the actual data is fat, muscle, and metabolic. Any “it’s good for your brain” claim is an extrapolation two steps removed from evidence — mechanism → assumed NAD⁺ rise → assumed cognitive benefit. That’s a hypothesis, not a finding, and it should be labelled as one.
A step down in evidence and up in risk. These are injectable or research-chemical compounds that aim to rewire — to grow synapses and drive plasticity. The ambition is real; the human data is not.
A synthetic ACTH(4-10) fragment; proposed mechanism is raising BDNF (the plasticity signal). Almost all research is Russian-origin with minimal Western replication, and it has no FDA approval.
A tuftsin analog; anxiolytic without sedation, proposed GABAergic and immune modulation. Same evidence problem as Semax: Russian-origin literature, sparse independent validation.
A porcine brain-derived peptide mixture with neurotrophic properties — actually the best-studied here, and used in some countries for stroke and dementia. But the evidence is mixed and effects modest at best, it requires injection, and being animal-derived it carries immunogenicity considerations.
An angiotensin-derived compound acting on the HGF/c-Met pathway, with dramatic rodent synaptogenesis claims. Here’s the problem: c-Met is a proto-oncogene — a growth-and-proliferation pathway implicated in cancer. A compound whose entire selling point is powerfully forcing a growth pathway carries exactly the structural concern that sank other force-the-switch compounds. There is no human safety data and no long-term studies. Understand it; don’t be the experiment.
Dihexa is the brain’s version of a lesson this platform keeps running into: forcing a master growth switch is the mechanism that most reliably produces both the headline benefit and the tail risk, because the pathways that build tissue are the pathways that make cells proliferate. When a compound’s pitch is “vastly more potent than the body’s own growth signal,” that potency is the risk, not a separate footnote to it.
Now the payoff — the layer map answers questions a flat list can’t:
Alpha-GPC and nicotine aren’t redundant — they hit one system at two points (substrate vs receptor), which is why they’re paired. Tyrosine and theanine are opposing poles — drive vs calm — so they balance or cancel depending on your goal; taking both without knowing which you want is just noise. DHA and vitamin D build the substrate everything else runs on — no signal-layer agent works well in a badly-built brain. And methylene blue, NAD⁺, and MOTS-c sit at the energy layer beneath all signaling, which is exactly why they feel broader and less targeted than a focus compound: they’re raising the account balance every signal draws on.
The deeper the layer, the more foundational but slower the effect. Signal-layer agents are felt in an hour. Structure and energy take weeks to months but raise the ceiling everything else operates under. Chasing only the fast-feeling ones is precisely how people end up with a drawer full of nootropics and a brain that is still under-fuelled and under-built. If you’re optimizing in the wrong order, the exciting layer can’t compensate for the boring one.
Brain agents aren’t a flat list — they act at four layers. Signal (acetylcholine via Alpha-GPC’s substrate or nicotine’s receptor; tyrosine for drive under stress; theanine and magnesium for calm) is what you feel, fast and shallow. Structure (DHA as membrane material, vitamin D as a hormone, K2 protecting the plumbing) is what the brain is made of — invisible and foundational. Energy (methylene blue = flow, NAD⁺ = fuel, MOTS-c = signal, with CoQ10/PQQ/ALCAR supporting) matters because the brain burns 20% of your energy on 2% of your weight. Growth (Semax, Selank, Cerebrolysin, Dihexa) is frontier — thin human data, and Dihexa forces a proto-oncogene. The deeper the layer, the slower it acts and the more everything else depends on it — so optimizing only what you can feel is optimizing in the wrong order.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment, and does not recommend any compound, dose, combination, or protocol for any individual. Several substances named (Semax, Selank, Cerebrolysin, Dihexa, MOTS-c, 5-Amino-1MQ) are unapproved research chemicals with limited or no human safety data. Nicotine is addictive and carries cardiovascular effects. Methylene blue has a narrow dose-response, interacts dangerously with serotonergic medications, and is contraindicated in G6PD deficiency. Supplements interact with each other and with prescription medication; decisions about use, dose, and combination belong with a qualified physician using appropriate testing. Evidence described ranges from established to speculative and is labelled accordingly.
This lesson relates to these health systems — health works as a connected system, not isolated topics.